Phaseline

Targets › PKMYT1

PKMYT1 (Membrane-associated tyrosine- and threonine-specific cdc2-inhibitory kinase): drug programs, companies and trials

2 programs from 2 companies in 2 trials: 2 Phase 1; Oncology; next expected readout Dec 2027.

Acts as a negative regulator of entry into mitosis (G2 to M transition) by phosphorylation of the CDK1 kinase specifically when CDK1 is complexed to cyclins. Mediates phosphorylation of CDK1 predominantly on 'Thr-14'. Also involved in Golgi fragmentation. (UniProt, Q99640)

Open in Phaseline: the race on PKMYT1, likelihood bands and readouts

Programs

CompanyDrugTargetsHighest phaseConditionsNext expected readout
Debiopharm InternationalLunresertib
PKMYT1 inhibitor
PKMYT1Phase 1Advanced Solid TumorDec 2027
University Health Network, TorontoRP-6306
PKMYT1 kinase inhibitor
PKMYT1Phase 1Recurrent Ovarian Cancer–

Conditions

Advanced Solid Tumor (1) Recurrent Ovarian Cancer (1)

Modalities

small molecule (2)

Companies

Debiopharm International (1) University Health Network, Toronto (1)

Related targets

–

Programs group each company's trials by drug; targets and mechanisms come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood is in the app.